CFDE Data Portal | Search LOC122539214

	Label	Description
	LOC122539214 Gene (Entity type)	ENSG00000269825 - Zinc finger protein LOC122539214
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 8 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239688 canagliflozin 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130246 enzalutamide UM 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE222758 clofazimine U2OS 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC122539214

ENSG00000269825 - Zinc finger protein LOC122539214

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up

A Gene Set from LINCS

GSE239844 crizotinib 8 v 10 human dn

A Gene Set from LINCS

GSE239688 canagliflozin 4 v 3 human dn

A Gene Set from LINCS

GSE130246 enzalutamide UM 1 v 3 human dn

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human dn

A Gene Set from LINCS

GSE146982 metformin 0 v 6 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

A Gene Set from LINCS

GSE222758 clofazimine U2OS 0 v 4 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.